The Role of Brucine A in Renal Fibrosis

Renal fibrosis is the common pathological basis for the progression of various chronic kidney diseases to end-stage renal disease, which is mainly manifested as renal tissue inflammatory infiltration, oxidative stress imbalance, renal tubular epithelial cell transdifferentiation and excessive extracellular matrix deposition. Currently, there are no effective targeted reversal methods in clinical practice. Brucine A (BA), a natural triterpenoid active ingredient, possesses significant anti-inflammatory, antioxidant and anti-fibrotic pharmacological activities.

It can inhibit renal inflammatory responses and oxidative stress damage, reduce the expression of fibrosis-related proteins and matrix accumulation by regulating key signaling pathways such as TGF-beta1 and NF-kB, thereby effectively delaying the progression of renal fibrosis. This study aims to systematically clarify the intervention effect of BA on renal fibrosis and reveal its potential molecular mechanism, so as to provide experimental evidence and theoretical basis for the prevention and treatment of chronic kidney diseases as well as the clinical transformation and application of BA.